Literature DB >> 26419441

Dental amalgam artifact: Adverse impact on tumor visualization and proton beam treatment planning in oral and oropharyngeal cancers.

Patrick Richard1, George Sandison2, Quang Dang3, Bart Johnson3, Tony Wong4, Upendra Parvathaneni2.   

Abstract

PURPOSE: We evaluated the incidence and impact of dental filling artifacts on the definition of clinical target volume (CTV) for oropharyngeal/oral cavity cancers receiving radiation therapy. We performed phantom proton beam dosimetric analyses using a low-density composite filling to investigate artifact reduction and dose distribution. METHODS AND MATERIALS: We reviewed oral cavity/oropharynx radiation treatment plans between 2010 and 2012. Plans were evaluated for artifacts and impact on CTV visualization. We constructed a head and neck phantom, obtaining planning computed tomography images at baseline (native tooth) and for each filling (composite and metal amalgam) interchanged into a tooth adjacent to the tumor. We performed uniform scanning proton plans with each filling, evaluating for planning target volume (PTV) coverage and overall dose distribution.
RESULTS: A total of 110 treatment plans were reviewed (71 oropharynx, 39 oral cavity). Artifacts were identified in 81 plans (73.6%), including 53 oropharynx (74.6%) and 28 oral cavity (71.8%). Artifacts obscured the CTV in 77 cases (95%), including 49 of 53 oropharynx cases (92.5%) and all 28 oral cavity cases. On phantom testing, the metal amalgam obscured the tumor while the composite did not. Hounsfield unit (HU) values (range, mean) for the tumor were: baseline (-484.0 to 700.0 HU, 104 HU), composite (-728.5 to 1038.0 HU, 105 HU), metal amalgam (-1023.0 to 807.0 HU, 90.74 HU). The percent of planning target volume receiving 95% of prescription dose of the PTV was baseline (100%), composite (100%), and metal amalgam (92.3%). PTV dose ranges were baseline (98%-106%), composite (98%-107%), and metal amalgam (66%-111%). PTV coverage and dose distributions of the composite and native tooth plans were identical.
CONCLUSIONS: A high incidence of artifacts was found on the planning scans of oral/oropharyngeal cancer patients, adversely impacting CTV visualization. In our phantom model, metal amalgam impacted tumor and tissue density. The PTV was underdosed with the metal amalgam compared with the composite filling. A potential solution involves exchanging metal fillings with composite before proton treatment planning for improved tumor visualization and dosimetry.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419441     DOI: 10.1016/j.prro.2015.04.007

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  4 in total

Review 1.  Dental management in head and neck cancers: from intensity-modulated radiotherapy with photons to proton therapy.

Authors:  Sabah Falek; Rajesh Regmi; Joel Herault; Melanie Dore; Anthony Vela; Pauline Dutheil; Cyril Moignier; Pierre-Yves Marcy; Julien Drouet; Arnaud Beddok; Noah E Letwin; Joel Epstein; Upendra Parvathaneni; Juliette Thariat
Journal:  Support Care Cancer       Date:  2022-05-05       Impact factor: 3.359

2.  Proton Therapy for Locally Advanced Oropharyngeal Cancer: Initial Clinical Experience at the University of Washington.

Authors:  Saif Aljabab; Andrew Liu; Tony Wong; Jay J Liao; George E Laramore; Upendra Parvathaneni
Journal:  Int J Part Ther       Date:  2019-12-19

3.  Development of a stereoscopic CT metal artifact management algorithm using gantry angle tilts for head and neck patients.

Authors:  Daniela Branco; Stephen Kry; Paige Taylor; John Rong; Xiaodong Zhang; Christine Peterson; Steven Frank; David Followill
Journal:  J Appl Clin Med Phys       Date:  2020-06-07       Impact factor: 2.102

4.  Intensity-Modulated Proton Therapy for Nasopharynx Cancer: 2-year Outcomes from a Single Institution.

Authors:  Vonetta M Williams; Upendra Parvathaneni; George E Laramore; Saif Aljabab; Tony P Wong; Jay J Liao
Journal:  Int J Part Ther       Date:  2021-04-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.